Cargando…
Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects
Little is known about the function and phenotype of leukemic stem cells (LSCs) in chronic myeloid leukemia (CML) or about specific markers that discriminate LSCs from normal hematopoietic stem cells (HSCs). CD26 has recently been described as a specific marker of CML LSCs. In the current study, we i...
Autores principales: | Culen, Martin, Borsky, Marek, Nemethova, Veronika, Razga, Filip, Smejkal, Jiri, Jurcek, Tomas, Dvorakova, Dana, Zackova, Daniela, Weinbergerova, Barbora, Semerad, Lukas, Sadovnik, Irina, Eisenwort, Gregor, Herrmann, Harald, Valent, Peter, Mayer, Jiri, Racil, Zdenek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078071/ https://www.ncbi.nlm.nih.gov/pubmed/27145281 http://dx.doi.org/10.18632/oncotarget.9108 |
Ejemplares similares
-
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019) -
Cell‐based and antibody‐mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues
por: Valent, Peter, et al.
Publicado: (2020) -
Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018) -
Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience
por: Weinbergerová, Barbora, et al.
Publicado: (2023) -
Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia
por: Knight, Andrea, et al.
Publicado: (2022)